$0.948100
0.066.28%
At Close: -
$0.920000
-0.03-2.96%
After Hours: Aug 23, 6:21 PM EDT
15 minutes delayed
Comments
Loading...
Lineage Cell Therapeutics (AMEX:LCTX) Stock, Earnings Estimates, EPS, And Revenue
Lineage Cell Therapeutics reports earnings on a quarterly basis. These quarterly earnings reports give investors a glimpse into financial results from a company for a 3 month period. Earnings reports almost always include EPS and Revenue results.
Earnings Date
Nov 7
EPS Estimate
$-0.040
Quarterly Revenue Estimate
$1.1M
Annual Revenue
(as of Jun 30)
(as of Jun 30)
$6.2M
Analyze the earnings history of Lineage Cell Therapeutics using advanced sorting and filters.
Data brought to you by Benzinga APIs
Lineage Cell Therapeutics (LCTX) Earnings Per Share
Quarterly Earnings Surprise Amount
| Fiscal Quarter End | Date Reported | Actual EPS | Estimated EPS | Surprise % |
|---|---|---|---|---|
| Jun 2024 | 2024-08-08 | $-0.03 | $-0.04 | 25.0 % |
| Mar 2024 | 2024-05-09 | $-0.04 | $-0.04 | 0.00 % |
| Dec 2023 | 2024-03-07 | $-0.03 | $-0.04 | 25.0 % |
| Sep 2023 | 2023-11-09 | $-0.04 | $-0.04 | 0.00 % |
Lineage Cell Therapeutics (LCTX) Revenue
Quarterly Revenue Surprise Amount
| Fiscal Quarter End | Date Reported | Actual Revenue | Estimated Revenue | Surprise % |
|---|---|---|---|---|
| Jun 2024 | 2024-08-08 | $1.41M | $970.00K | 45.1 % |
| Mar 2024 | 2024-05-09 | $1.44M | $1.36M | 6.18 % |
| Dec 2023 | 2024-03-07 | $2.10M | $1.31M | 60.3 % |
| Sep 2023 | 2023-11-09 | $1.25M | $2.59M | -51.9 % |
FAQ
When is Lineage Cell Therapeutics (AMEX:LCTX) reporting earnings?
Lineage Cell Therapeutics (LCTX) is scheduled to report earnings on November 7, 2024. The last reported earnings were for reported on August 8, 2024 for Q2.
What were the latest earnings per share (EPS) for Lineage Cell Therapeutics (AMEX:LCTX)?
The Actual EPS was $-0.03, which beat the estimate of $-0.04.
What were Lineage Cell Therapeutics’s (AMEX:LCTX) revenues?
The Actual Revenue was $1.4M, which beat the estimate of $970K.
Browse earnings estimates, EPS, and revenue on all stocks.